Is the combination of amlodipine and benazepril considered guideline-directed medical therapy (GDMT) for heart failure (HF)?

No, amlodipine/benazepril is NOT guideline-directed medical therapy (GDMT) for heart failure

The combination of amlodipine and benazepril is not considered GDMT for heart failure with reduced ejection fraction (HFrEF). While benazepril (an ACE inhibitor) is a cornerstone of HF therapy, amlodipine (a calcium channel blocker) is specifically recommended against for routine use in HFrEF.

Current GDMT for HFrEF: The Four Pillars

Modern GDMT for HFrEF consists of four foundational drug classes that should be initiated early and used in combination 1, 2, 3, 4:

1. ACE inhibitor/ARB/ARNI (Angiotensin receptor-neprilysin inhibitor)
2. Beta-blocker (evidence-based: bisoprolol, carvedilol, metoprolol succinate)
3. Mineralocorticoid receptor antagonist (MRA) (spironolactone or eplerenone)
4. SGLT2 inhibitor (dapagliflozin or empagliflozin)

Why Amlodipine is NOT Part of GDMT

Strong Evidence Against Routine Use

Calcium channel blockers are explicitly recommended against for routine use in HFrEF 5, 3. The 2017 Canadian guidelines provide a Strong Recommendation with Moderate-Quality Evidence against routine CCB use in HFrEF 5.

The evidence base is clear:

• PRAISE-1 and PRAISE-2 trials: Amlodipine showed no mortality benefit in HFrEF patients 6. While PRAISE-1 suggested benefit in a nonischemic cardiomyopathy subgroup, PRAISE-2 (which specifically enrolled only nonischemic patients) found no significant difference in all-cause mortality and reported more pulmonary edema with amlodipine 6.

• 2022 AHA/ACC/HFSA Guidelines: Second-generation dihydropyridine CCBs (amlodipine, felodipine) showed no survival benefit in dedicated HF trials 3.

Limited Acceptable Use

Amlodipine may only be considered for specific indications in HFrEF patients 5:

• Persistent hypertension despite optimal GDMT
• Angina symptoms despite GDMT

Even in these scenarios, it's an add-on therapy for symptom control, not a foundational GDMT component.

Non-dihydropyridine CCBs are Contraindicated

Diltiazem and verapamil are explicitly contraindicated in HFrEF (Class III recommendation) as they increase risk of HF worsening and hospitalization 1, 3.

The Benazepril Component: Appropriate but Incomplete

While benazepril (an ACE inhibitor) is appropriate GDMT 1, 3, using it in fixed combination with amlodipine:

1. Limits dosing flexibility: You cannot titrate the ACE inhibitor to target HF doses without increasing amlodipine exposure
2. Adds unnecessary medication: The amlodipine component provides no mortality/morbidity benefit in HF
3. May cause harm: Potential for increased pulmonary edema 6

The ACCOMPLISH Trial Context

The ACCOMPLISH trial 7 showed benazepril-amlodipine superior to benazepril-hydrochlorothiazide for cardiovascular outcomes in hypertensive patients at high cardiovascular risk—not HF patients. This was a hypertension trial, and the guidelines explicitly state this combination is for "selected patients at high risk for cardiovascular events" with poorly controlled blood pressure 7, not for HF management.

Practical Clinical Approach

If a patient with HFrEF is on amlodipine/benazepril:

1. Separate the components: Switch to benazepril alone (or preferably an ARNI like sacubitril/valsartan)
2. Discontinue amlodipine unless there's a compelling indication (refractory hypertension or angina despite GDMT)
3. Initiate the other three GDMT pillars: Beta-blocker, MRA, and SGLT2 inhibitor
4. Titrate to target doses of all four medication classes 2, 3, 4

Common Pitfall to Avoid

Do not confuse hypertension management with HF management. The combination may be appropriate for hypertension with high cardiovascular risk 7, but HFrEF requires specific evidence-based therapies that reduce mortality and HF hospitalizations 1, 3, 4. The goals and evidence base are fundamentally different.